Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2).

about

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2).

Item

http://www.wikidata.org/entity/Q52584491

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Anti-VEGF treatment of macular ...... ractice (ECHO study report 2).

@en

Anti-VEGF treatment of macular ...... ctiveness in clinical practice

@nl

type

Item

label

Anti-VEGF treatment of macular ...... ractice (ECHO study report 2).

@en

Anti-VEGF treatment of macular ...... ctiveness in clinical practice

@nl

prefLabel

Anti-VEGF treatment of macular ...... ractice (ECHO study report 2).

@en

Anti-VEGF treatment of macular ...... ctiveness in clinical practice

@nl

P1476

Anti-VEGF treatment of macular ...... practice (ECHO study report 2)

@en

P2093

J Michael Jumper

http://www.w3.org/2001/XMLSchema#string

John G Walt

http://www.w3.org/2001/XMLSchema#string

Pravin U Dugel

http://www.w3.org/2001/XMLSchema#string

Sanford Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.

Central and hemicentral retinal vein occlusion: role of anti-platelet aggregation agents and anticoagulants.

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis.

Bevacizumab Versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study.

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

P304

621-629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OPTH.S163859

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kevin J Blinder

P577

2018-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29662298

http://www.w3.org/2001/XMLSchema#string

P932

5892950

http://www.w3.org/2001/XMLSchema#string